Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000542
First received: October 27, 1999
Last updated: February 4, 2009
Last verified: February 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Show Detailed Description
To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
Condition | Intervention | Phase |
---|---|---|
Cardiovascular Diseases Coronary Disease Diabetes Mellitus Heart Diseases Hypercholesterolemia Hypertension Myocardial Infarction Myocardial Ischemia Heart Failure |
Drug: Inhibitors, ACE Drug: amlodipine Drug: lisinopril Drug: doxazosin Drug: chlorthalidone Drug: pravastatin Behavioral: diet, fat-restricted |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Primary Purpose: Prevention |
Resource links provided by NLM:
MedlinePlus related topics:
Blood Pressure Medicines
Cholesterol
Coronary Artery Disease
Diabetes
Heart Attack
Heart Diseases
Heart Failure
High Blood Pressure
Drug Information available for:
Chlorthalidone
Doxazosin
Lisinopril
Doxazosin mesylate
Pravastatin
Pravastatin sodium
Amlodipine
Amlodipine besylate
U.S. FDA Resources
Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):
Study Start Date: | August 1993 |
Study Completion Date: | March 2002 |
Primary Completion Date: | March 2002 (Final data collection date for primary outcome measure) |
Eligibility
Ages Eligible for Study: | 55 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Men and women hypertensive patients, ages 55 and above. A total of 36 percent were diabetics.
Contacts and Locations
More Information
Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 14, 2013
Additional Information:
Related Info 
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00000542 History of Changes |
Other Study ID Numbers: | 85 |
Study First Received: | October 27, 1999 |
Last Updated: | February 4, 2009 |
Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
Cardiovascular Diseases Myocardial Ischemia Coronary Artery Disease Coronary Disease Diabetes Mellitus Heart Diseases Heart Failure Hypercholesterolemia Hypertension Infarction Ischemia Myocardial Infarction Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases |
Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Pathologic Processes Necrosis Angiotensin-Converting Enzyme Inhibitors Lisinopril Antihypertensive Agents Chlorthalidone Amlodipine Doxazosin Pravastatin |
ClinicalTrials.gov processed this record on February 14, 2013